Brinda Venkateshaiah

• Designed, executed, and interpreted biochemical and cell-based assays to characterize target protein function in IBD-relevant signaling pathways, supporting early discovery and indication strategy.
• Investigated effects of IBD-relevant stimuli on target expression and downstream molecular readouts, confirming biological relevance for pipeline programs.
• Performed high-throughput, SAR-driving assays using human whole blood and reporter cell lines to enable rapid, data-driven compound prioritization.
• Prepared RNA for sequencing and conducted orthogonal validation studies (qPCR, protein assays) to confirm transcriptomic findings.
• Collaborated with analytical and mass spectrometry teams to assess compound target engagement across human and preclinical species, supporting translational decision-making.
• Maintained detailed experimental records in an electronic laboratory notebook (ELN), ensuring data integrity, reproducibility, and compliance with internal standards.
• Presented experimental results at project team, cross-functional, and leadership meetings, contributing to program advancement decisions.

• Processed primary tissues (colon, small intestine, bone marrow, liver) to isolate, culture, and bank cells from mouse, rat, pig, and human sources to support GI, rare disease, and liver fibrosis programs.
• Regularly generated enteric stem cell derived 3D neurosphere cultures from mouse colon to support neuro-gastroenterology discovery programs.
• Optimized cell culture conditions, media formulations, and assay workflows to improve robustness and reproducibility.
• Executed phenotypic characterization studies and bioactivity assessments to drive assay development and protocol refinement.
• Managed lab operations through inventory oversight, ordering reagents/supplies for the team.

• Processed adipose donor samples with the InGeneron Transpose RT Ultra medical device.
• Scaled-up production through routine expansion and banking of adipose-derived stem cells (ASCs) for preclinical use.
• Executed migration and micro-chemotaxis assays to evaluate the therapeutic potential of ASCs in tendon healing.
• Conducted gene expression analysis on ASCs to characterize stem cell and differential lineage markers (adipogenic and osteogenic).

• Conducted in vitro assays to assess cell viability, proliferation, and metabolic activity in support of evaluating OxPhos-modulating therapeutics.

• Prepared a literature review highlighting key findings in oncology, immunotherapy, and fibrosis to explain the basis for OxPhos-modulating drug development to investors and partners.